VIDEO: Bimekizumab efficacious in severe psoriasis, may increase yeast infection risk
Click Here to Manage Email Alerts
In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed study results presented at the American Academy of Dermatology Annual Meeting examining bimekizumab in the treatment of psoriasis.
Feldman, professor of dermatology, pathology and social sciences and health policy at Wake Forest University School of Medicine, discussed safety data into bimekizumab (Bimzelx, UCB) for plaque psoriasis, which showed that the interleukin-17 blocker works quickly and effectively, with the drawback of added risk for yeast infections.
“You get greater efficacy for the skin and the joints. It works really fast,” Feldman said, adding it may currently be the fastest acting drug in treating severe psoriasis. “And the cost is possibly getting a yeast infection for which you might need a Diflucan [fluconazole, Pfizer] pill.”